Trifast’s pre-close trading update indicates another strong year of execution of the company’s well-developed growth strategy. The profit before tax for FY18 is slightly ahead of management expectations, with investment continuing to support growth. A strong order pipeline at the year-end serves to underpin confidence in continued organic progression. The acquisition of Precision Technology Supplies (PTS) in the UK on 4 April 2018 should also make a full-year earnings enhancing contribution, and we have raised our forecasts for FY19 accordingly.
Written by
Trifast |
Encouraging momentum into FY19 |
Pre-close trading update |
Industrial support services |
20 April 2018 |
Share price performance
Business description
Next events
Analysts
Trifast is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
Trifast’s pre-close trading update indicates another strong year of execution of the company’s well-developed growth strategy. The profit before tax for FY18 is slightly ahead of management expectations, with investment continuing to support growth. A strong order pipeline at the year-end serves to underpin confidence in continued organic progression. The acquisition of Precision Technology Supplies (PTS) in the UK on 4 April 2018 should also make a full-year earnings enhancing contribution, and we have raised our forecasts for FY19 accordingly.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
03/16 |
161.4 |
16.0 |
9.99 |
2.80 |
27.6 |
1.0 |
03/17 |
186.5 |
20.5 |
12.82 |
3.50 |
21.5 |
1.3 |
03/18e |
196.9 |
21.8 |
13.50 |
3.65 |
20.4 |
1.3 |
03/19e |
209.7 |
23.0 |
14.18 |
3.80 |
19.5 |
1.4 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
FY18 trading slightly ahead of expectations
All territories delivered organic revenue growth in the year ending 31 March 2018, and with the exception of the US, all contributed increased profitability. Overall investment in organic development continued with benefits from ongoing high levels of investment expected to continue in the current year. The balance sheet continues to be robust as disciplined working capital management has allowed maintenance of strong cash conversion despite the high levels of investment. We have reduced our FY18 revenue by 1%, reflecting Q418’s adverse FX movements but increase our PBT estimates by 2% to reflect the slight beat of management expectations. The company will provide full detail with its results on 12 June 2018.
Solid progress expected in FY19
Although the macroeconomic situation remains broadly unchanged, some of the FX-related pressures have eased during H218. FX volatility and raw material prices remain largely outside management’s immediate control, as does the potential effects from the path towards Brexit. As yet domestic demand remains fairly steady. The investments already completed should continue to deliver both volume and margin benefits, notably in Singapore, and PTS should add around £6m of sales with a mid-teen margin. Even allowing for the £8.5m initial acquisition cost of PTS, the company retains adequate resources to pursue both organic and M&A investments, including an anticipated project to upgrade IT infrastructure.
Valuation: Rating more aligned with peers
Trifast’s share price performance has continued to reflect the continued success of the strategy, moving closer to its all-time high. We have increased our FY19e revenues by 2%, and our PBT and EPS estimates by 5%, largely to reflect the purchase of PTS. The FY19e P/E of almost 20x is now far more consistent with its immediate peer group.
FY18 trading update
All territories delivered organic revenue growth in the year ending 31 March 2018, and with the exception of the US, all contributed increased profitability.
Europe has experienced sequentially stronger organic sales growth in H218, with good growth in a number of key end-market sectors, notably the automotive operations in Sweden and Holland, which experienced healthy double-digit demand. The new Spanish greenfield site and the electric vehicle development centre in Gothenburg should support continuing growth in automotive. In domestic appliances, the volumes return to more normal levels following the previous product recall by a customer that boosted demand. The debottlenecking of manufacturing in Italy in FY17 provides additional capacity to meet demand increases.
In the UK, FY18 proved to be a healthy year for sales through European distributor channels as well as healthy demand from multinational OEMs.
Asia continued to perform well, with solid organic growth during the year across the key automotive and domestic appliance sectors. Although the pace of growth moderated in Asia during the second half, this was expected. This was partly due to continued margin discipline being displayed in the region, with some volume sacrificed as a result of unfavourable outcomes in e-bidding auction processes, as well as a restructuring at one key automotive customer.
The US continued to recover from the impact of Hurricane Harvey in August and the company continues to invest to drive growth in the region.
Overall investment in organic development continued with the previous debottlenecking in Italy expansion delivering benefits during the year, and the expansion of manufacturing in Singapore achieved towards the year end. Warehouse expansions in Holland and the US are expected to be delivered this year, with the new Shanghai warehouse providing support for automotive growth in China and Japan. Despite the high levels of investment, the balance sheet continues to be robust as disciplined working capital management has allowed maintenance of strong cash conversion.
Outlook for FY19
In the UK the macroeconomic backdrop has so far proved more resilient than some had forecast, although some domestic uncertainties remain, notably around Brexit impacts. The recent announcement of production cutbacks at Jaguar Land Rover is likely to have an adverse effect, but this is more company specific, driven by falling diesel vehicle sales in the UK. However, the FX rates have reversed over the last year and while this may mitigate some margin pressure from higher input costs, the positive impact of this is likely to be deferred until later in the coming year and it may slow growth in distributor sales to the continent. Performance in the UK in FY19 will be enhanced as PTS will also make its initial contribution, effectively for a full year.
Asia should benefit from the manufacturing capacity expansion in Singapore, which should lift margins with better overhead absorption. The new warehouse in Shanghai should also support continued automotive sector growth in China and Japan.
We would expect to see H1 recovery in the US assuming no repeat of the weather events in FY18. Management continues to build the team and invest in new facilities to support growth, including the opening of a larger warehouse and office facility in Houston this month.
The company has now scoped a project to integrate and develop the IT infrastructure across the group to support the continuing growth and improving the interface with customers. The associated costs are likely to be a major element of investment over the next couple of years.
Acquisition of PTS
On 4 April 2018 Trifast purchased PTS in the UK. The company is a key supplier and distributor of stainless steel fasteners with one of the broadest product ranges in Europe, significantly extending Trifast’s offering in this area. The deal should be immediately EPS enhancing and, assuming recent growth trends continue, value creation looks readily achievable.
PTS is being bought for £8.5m initially, with an earnout that could cost a further £2.5m. Based on data for the year ended March 2017, we estimate the initial consideration represents a historic P/E multiple of around 15x, although growth in FY18 should reduce the multiple significantly. With a pre-tax margin of around 14% and the purchase being funded from existing facilities, the deal should be EPS enhancing in FY19. Combining medium-term synergy benefits expected from more efficient sourcing with further growth, the deal should be value creating. In the current year we expect PTS to contribute £6m to revenues with a mid-teen operating margin, above the UK regional average.
Founded in 1988, PTS is based in East Grinstead, close to Trifast’s headquarters in Uckfield. PTS has some 43,000 part numbers available for its customers in 80 countries, significantly expanding Trifast’s range in stainless steel products. In addition to extending Trifast’s customer base, PTS should increase presence in sectors such as electronics, medical instruments, petrochemical, defence and robotics.
Following the acquisition, Trifast retains adequate financial resources to pursue further appropriate M&A opportunities as they arise.
Revisions to FY19 estimates
The slightly more positive outturn to FY18 and confidence in organic progression for FY19 would have led to a modest increase in expectations for FY19, but the prospects are further augmented by a significant and almost full year contribution from PTS.
As a result we have lifted our revenue, PBT and EPS estimates by 5.0%. The increase in expected net debt is largely a reflection of the consideration for the acquisition of PTS.
Exhibit 1: Revisions to Trifast earnings estimates
(£m) |
2018e |
2019e |
||||
|
Prior |
New |
% change |
Prior |
New |
% change |
UK |
69.2 |
69.2 |
0.0% |
70.5 |
76.7 |
8.7% |
Europe |
71.3 |
70.6 |
-0.9% |
72.7 |
72.7 |
0.0% |
USA |
6.5 |
6.4 |
-0.9% |
7.1 |
7.1 |
-0.9% |
Asia |
52.1 |
50.7 |
-2.7% |
54.7 |
53.3 |
-2.7% |
Total group revenue |
199.1 |
196.9 |
-1.1% |
205.1 |
209.7 |
2.2% |
|
|
|
|
|
|
|
EBITDA |
23.5 |
24.0 |
2.1% |
24.1 |
25.4 |
5.6% |
|
|
|
|
|
|
|
EBIT by region |
||||||
UK |
8.1 |
8.5 |
4.6% |
7.8 |
9.5 |
22.5% |
Europe |
7.8 |
8.6 |
10.9% |
8.0 |
8.7 |
9.1% |
USA |
0.3 |
0.3 |
-0.9% |
0.6 |
0.5 |
-13.3% |
Asia |
9.1 |
8.4 |
-7.6% |
9.6 |
8.5 |
-11.4% |
HQ Other and intersegment |
(3.7) |
(3.7) |
0.0% |
(3.7) |
(3.7) |
0.0% |
EBIT (Pre PPA amortisation) |
21.6 |
22.2 |
2.4% |
22.2 |
23.5 |
5.9% |
|
|
|
|
|
|
|
Underlying PBT |
21.3 |
21.8 |
2.4% |
21.9 |
23.0 |
5.0% |
|
|
|
|
|
|
|
EPS - underlying continuing (p) |
13.19 |
13.50 |
2.4% |
13.51 |
14.18 |
5.0% |
DPS (p) |
3.65 |
3.65 |
0.0% |
3.80 |
3.80 |
0.0% |
Net cash/(debt) |
(5.1) |
(7.3) |
41.5% |
0.1 |
(10.7) |
N/M |
Source: Edison Investment research estimates
Exhibit 2: Financial summary
£000s |
2016 |
2017 |
2018e |
2019e |
||
Year end 31 March |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||
Revenue |
|
|
161,370 |
186,512 |
196,933 |
209,735 |
Cost of Sales |
(113,366) |
(128,495) |
(137,263) |
(146,185) |
||
Gross Profit |
48,004 |
58,017 |
59,671 |
63,550 |
||
EBITDA |
|
|
18,150 |
22,868 |
23,952 |
25,427 |
Operating Profit (before amort. and except.) |
16,793 |
21,018 |
22,160 |
23,519 |
||
Intangible Amortisation |
(974) |
0 |
0 |
0 |
||
Exceptionals |
(264) |
(1,645) |
(1,123) |
(1,123) |
||
Other |
(1,687) |
(1,512) |
(2,200) |
(2,200) |
||
Operating Profit |
13,868 |
17,861 |
18,837 |
20,229 |
||
Net Interest |
(791) |
(521) |
(383) |
(544) |
||
Profit Before Tax (norm) |
|
|
16,002 |
20,497 |
21,777 |
22,974 |
Profit Before Tax (FRS 3) |
|
|
13,077 |
17,340 |
18,454 |
19,651 |
Tax |
(3,984) |
(4,835) |
(5,118) |
(5,399) |
||
Profit After Tax (norm) |
12,018 |
15,662 |
16,659 |
17,575 |
||
Profit After Tax (FRS 3) |
10,225 |
12,698 |
14,117 |
15,033 |
||
Average Number of Shares Outstanding (m) |
116.4 |
118.5 |
119.8 |
120.3 |
||
EPS - normalised (p) |
|
|
9.99 |
12.82 |
13.50 |
14.18 |
EPS - (IFRS) (p) |
|
|
8.79 |
10.72 |
11.79 |
12.50 |
Dividend per share (p) |
2.80 |
3.50 |
3.65 |
3.80 |
||
Gross Margin (%) |
29.7 |
31.1 |
30.3 |
30.3 |
||
EBITDA Margin (%) |
11.2 |
12.3 |
12.2 |
12.1 |
||
Operating Margin (before GW and except.) (%) |
10.4 |
11.3 |
11.3 |
11.2 |
||
BALANCE SHEET |
||||||
Fixed Assets |
|
|
55,430 |
58,940 |
59,215 |
67,830 |
Intangible Assets |
38,259 |
39,682 |
38,559 |
43,936 |
||
Tangible Assets |
17,171 |
19,258 |
20,656 |
23,894 |
||
Investments |
0 |
0 |
0 |
0 |
||
Current Assets |
|
|
102,603 |
118,290 |
126,065 |
137,740 |
Stocks |
39,438 |
41,926 |
45,689 |
48,659 |
||
Debtors |
43,386 |
49,360 |
53,172 |
57,677 |
||
Cash |
17,614 |
24,645 |
24,645 |
28,645 |
||
Other |
2,165 |
2,359 |
2,559 |
2,759 |
||
Current Liabilities |
|
|
(52,813) |
(54,564) |
(50,354) |
(44,601) |
Creditors |
(35,879) |
(39,692) |
(38,482) |
(38,729) |
||
Short term borrowings |
(16,934) |
(14,872) |
(11,872) |
(5,872) |
||
Long Term Liabilities |
|
|
(21,470) |
(20,968) |
(24,881) |
(38,267) |
Long term borrowings |
(16,675) |
(16,221) |
(20,057) |
(33,440) |
||
Other long term liabilities |
(4,795) |
(4,747) |
(4,824) |
(4,827) |
||
Net Assets |
|
|
83,750 |
101,698 |
110,044 |
122,701 |
CASH FLOW |
||||||
Operating Cash Flow |
|
|
15,873 |
22,887 |
15,500 |
18,619 |
Net Interest |
(804) |
(521) |
(383) |
(544) |
||
Tax |
(3,080) |
(5,136) |
(5,118) |
(5,399) |
||
Capex |
(2,323) |
(2,948) |
(3,190) |
(3,146) |
||
Acquisitions/disposals |
(7,684) |
(1,471) |
0 |
0 |
||
Financing |
(2,122) |
46 |
(3,500) |
(8,500) |
||
Dividends |
(2,440) |
(3,310) |
(4,145) |
(4,413) |
||
Net Cash Flow |
(2,580) |
9,547 |
(836) |
(3,383) |
||
Opening net debt/(cash) |
|
|
13,415 |
15,995 |
6,448 |
7,284 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
15,995 |
6,448 |
7,284 |
10,667 |
Source: Company reports, Edison Investment Research estimates
|
|
Adocia is a clinical-stage biotech company that leverages its proprietary BioChaperone (BC) platform technology to generate improved formulations of approved products for diabetes. Its most advanced asset is BC Lispro, an ultra-fast formulation of insulin lispro ready to enter Phase III trials, after Lilly terminated a partnership agreement. Adocia has recently started a clinical study with BC Pramlintide Insulin and plans to start two more clinical trials in 2018 with its hormonal products, BC Glucagon GLP-1 and BC GLP-2. End 2017 net cash was €27.5m.